- Home
- ASR vs JAZZ Comparison
ASR vs JAZZ Comparison
Compare ASR & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASR
- JAZZ
- Stock Information
- Founded
- ASR 1996
- JAZZ 2003
- Country
- ASR Mexico
- JAZZ Ireland
- Employees
- ASR N/A
- JAZZ N/A
- Industry
- ASR Aerospace
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- ASR Consumer Discretionary
- JAZZ Health Care
- Exchange
- ASR Nasdaq
- JAZZ Nasdaq
- Market Cap
- ASR 7.8B
- JAZZ 6.5B
- IPO Year
- ASR 2000
- JAZZ 2007
- Fundamental
- Price
- ASR $276.05
- JAZZ $125.04
- Analyst Decision
- ASR Buy
- JAZZ Buy
- Analyst Count
- ASR 4
- JAZZ 14
- Target Price
- ASR $274.00
- JAZZ $173.93
- AVG Volume (30 Days)
- ASR 48.6K
- JAZZ 539.6K
- Earning Date
- ASR 10-22-2024
- JAZZ 11-06-2024
- Dividend Yield
- ASR 6.44%
- JAZZ N/A
- EPS Growth
- ASR 23.91
- JAZZ 458.10
- EPS
- ASR 2.16
- JAZZ 7.04
- Revenue
- ASR $1,490,558,036.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- ASR $18.66
- JAZZ $7.51
- Revenue Next Year
- ASR $17.41
- JAZZ $6.82
- P/E Ratio
- ASR $12.85
- JAZZ $17.38
- Revenue Growth
- ASR 11.33
- JAZZ 5.23
- 52 Week Low
- ASR $248.88
- JAZZ $99.06
- 52 Week High
- ASR $357.90
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- ASR 58.87
- JAZZ 56.71
- Support Level
- ASR $258.00
- JAZZ $121.73
- Resistance Level
- ASR $278.77
- JAZZ $126.23
- Average True Range (ATR)
- ASR 6.53
- JAZZ 2.79
- MACD
- ASR 1.88
- JAZZ -0.16
- Stochastic Oscillator
- ASR 89.00
- JAZZ 68.98
About ASR Grupo Aeroportuario del Sureste S.A. de C.V.
Grupo Aeroportuario del Sureste SAB de CV operates airports in southeast Mexico. The company's segments include Cancun; Aerostar; Airplan; Merida; Villahermosa; Holding and Services and other. It generates maximum revenue from the Cancun segment.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.